Patients with chronic pain treated with the novel FAST SCS systems may achieve significant and durable pain relief for up to 12 months of follow-up.

Boston Scientific (NYSE:BSX – Get Free Report) had its price target upped by equities researchers at Canaccord Genuity Group from $98.00 to $101.00 in a research report issued on Monday,Benzinga ...